Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
The purpose of this study is to see if one year of treatment with olaparib is better than observation alone in patients who had pancreatic cancer surgically removed and who have mutations in the BRCA1, BRCA2 or PALB2 genes. Olaparib is a type of anticancer medication called a PARP inhibitor, which may slow down the process cancer cells use to repair their DNA. Cancer cells need to repair their DNA to survive and grow.
The purpose of this study is to find the highest dose of the drug alectinib that can be given safely in children and adolescents with solid tumors or brain and spinal cord cancers that persist after treatment and have a genetic change called an ALK gene fusion. With this gene fusion, the ALK gene attaches to part of another gene.
The purpose of this study is to find the highest dose of the investigational drug STK-012 that can be given safely in combination with pembrolizumab immunotherapy to people with solid tumors that have spread or come back despite prior treatment. STK-012 is a modified form of a protein called interleukin-2, which is normally made by the immune system. It may help to multiply and activate tumor-killing cells of the immune system.
The purpose of this study is to assess the safety and effectiveness of treatment with axitinib and nivolumab immunotherapy for people with advanced mucosal melanoma that has not yet been treated. Axitinib blocks the development of blood vessels that cancer cells need to grow and spread ("angiogenesis"). Nivolumab boosts the ability of the immune system to detect and destroy cancer cells.
Rhabdomyosarcoma (RMS) is a type of cancer that occurs in the soft tissues in the body. Researchers in this study are comparing different chemotherapy-based treatments for children and young adults with very low-risk RMS, low-risk RMS, and RMS with DNA mutations, with treatment tailored to the predicted aggressiveness of each patient's cancer. The standard chemotherapy drugs participants will receive include vincristine, dactinomycin, and cyclophosphamide.
The purpose of this study is to find the highest dose of the investigational drug ASP3082 that can be given safely in people with inoperable or metastatic solid tumors that contain a mutation called KRAS G12D. ASP3082 targets the KRAS G12D mutation, blocking its ability to send signals that turn on cancer cells and cause them to grow and spread. It is given intravenously (by vein) through a central venous port on a weekly schedule.
The current standard treatment for throat cancer that is positive for the human papillomavirus (HPV) is 7 weeks of daily radiation therapy given together with chemotherapy, but this treatment can have severe side effects. In this study, researchers are assessing significantly lower doses of radiation (3 weeks) to achieve local and regional control of the tumor with significantly fewer side effects. Treatments will be given in combination with lower doses of chemotherapy (cisplatin, carboplatin, and 5-fluorouracil) as well in people with HPV-positive throat cancer.
